ArticleAmerican journal of translational research2022
Risk factor of brain metastases and its influence on patient prognosis after complete resection of non-small cell lung cancer.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Brain Metastasis After Curative Resection of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.Cureus · 2026Review
- Prognostic implications of MDM2 expression in surgically resected epidermal growth factor receptor mutant lung cancer with pathological lymph node metastasis.Translational lung cancer research · 2025Article
- Predictive risk score for isolated brain metastasis in non-small cell lung cancer.Journal of thoracic disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the risk factors of brain metastases and its influence on the prognosis of patients with complete resected non-small cell lung cancer (NSCLC).
methodsThe clinical data of 190 patients with completely resected NSCLC were retrospectively analyzed. The effect of brain metastasis on prognosis in patients with NSCLC after complete resection was investigated. The identification of risk factors for brain metastases was conducted by single-factor and Cox multivariate regression analysis.
resultsAmong 190 patients, 9 patients were lost to follow up. Finally, 181 patients were included in this study. The median survival time of brain metastases patients (64 cases) was 700 days. At 1 year, 3 years, and 5 years after surgery, the survival rates of patients with brain metastases were 62.5%, 28.13% and 7.81% respectively. Compared with those in patients without brain metastases, significant differences were found for median survival time and survival rates (P < 0.05). The Single-factor and multivariate Cox regression analysis indicated that the level of preoperative carcinoembryonic antigen (CEA), the lymph node ratio (≥ 30%) and non-squamous carcinoma type were risk factors for brain metastasis (P < 0.05).
conclusionsBrain metastasis is a risk factor for mortality in NSCLC patients after complete resection. Preoperative CEA levels, lymph node ratio (≥ 30%), and type of non-squamous cell carcinoma were risk factors for brain metastases.
Indexed as
Identifiers
35173859PMC8829628W4213392404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.